Teleflex (TFX) faces significant valuation challenges after a 69% decline over the past five years, prompting mixed analyst views on its recovery potential. Recent strategic decisions, including the ...

Teleflex is selling its acute care, interventional urology, and original equipment manufacturer (OEM) businesses in two separate deals totalling over $2bn as part of the company’s broader portfolio ...

Teleflex (TFX) has agreed to sell its acute care, interventional urology and OEM businesses to two buyers for a combined $2.03 billion in cash, subject to adjustments. Intersurgical will acquire the ...

Teleflex stock (NYSE: TFX), best known for its single-use medical devices for common diagnostic and therapeutic procedures, has seen a 31% fall this year, underperforming the broader S&P500 index, ...

After announcing plans to split up the company near the top of this year, Teleflex said it has found new homes for its businesses spanning acute care, urology and medical hardware manufacturing. Two ...

In the last three months, 5 analysts have published ratings on Teleflex (NYSE:TFX), offering a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of ...

Teleflex Incorporated presented new clinical data at the 2025 American Urological Association Annual Meeting, highlighting the UroLift™ System as a leading minimally invasive treatment for benign ...

Teleflex Incorporated (NYSE:TFX) reported better-than-expected earnings for the third quarter on Thursday. The company posted quarterly earnings of $3.67 per share which beat the analyst consensus ...

Teleflex is inking a $650 million deal to acquire Palette Life Sciences, the maker of urologic spacer implants and tissue bulking products. The agreement includes $600 million in upfront cash, plus ...

New, independent, publicly traded company (NewCo) consisting of Teleflex’s Urology, Acute Care, and OEM businesses. RemainCo will consist of Teleflex’s Vascular Access, Interventional, and Surgical ...